Kairos Pharma, Ltd. ( (KAPA) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kairos Pharma, Ltd. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is the need for additional time by the company’s accounting staff to prepare and finalize the financial statements. The company expects to file the report within the 15-day extension period allowed by the SEC. There are no anticipated significant changes in the financial results from the previous year, as indicated in their forward-looking statements. Kairos Pharma is committed to ongoing compliance, and the notification was signed by CEO John S. Yu.
More about Kairos Pharma, Ltd.
YTD Price Performance: -36.60%
Average Trading Volume: 2,388,969
Technical Sentiment Signal: Strong Buy
See more data about KAPA stock on TipRanks’ Stock Analysis page.